These suggest that CAF in tumor microenvironment promotes the progress of GC through IL-6/JAK2/STAT3 signal transduction, and IL-6 targeted therapy may become a complementary treatment for GC by acting on stromal fibroblasts (6). The gene discussed is JAK2; the disease is neoplasm.